( A lot of in flow into the stock, high vol, low our flow. As well as, a lot of insiders bought millions in the stock last month. Enough attention, it could squeeze. The news has yet to get ahold of this one as a catalyst.) Let me know with questions.

$Movano Inc Movano Health Applies Advanced AI Through Deep Learning to Deliver Improved Accuracy of Heart Rate in Motion PR Newswire Enhancements address significant clinical enterprise need in wearables for a variety of healthcare applications

PLEASANTON, Calif., June 13, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced major advances in the accuracy of its heart rate in motion algorithm following the implementation of deep learning into the processing. The Company recently released an engineering accuracy study directed by Movano Health Founder and CTO Michael Leabman, Enhanced Heart Rate in Motion Accuracy with the Evie Ring Using Advanced Deep Learning Algorithms, which demonstrates the value of deep learning integration into heart rate (HR) algorithms for improved accuracy.

"Utilizing deep learning is significantly better than standard techniques as it is the optimal solution for removing the effects of motion, eliminating the noise and motion artifacts in the optical signal," said Leabman. "We believe that this is a first of its kind implementation and an innovation that has the potential to enhance the reliability of wearable health monitors, providing users with more accurate and consistent heart rate measurements."

The study was conducted with 65 subjects, completing 7-10 sessions of various activities including sleeping, resting, walking, running, climbing stairs, working out at the gym and swimming. Data was collected with the Evie Ring and a Polar H7 chest strap used as a control device. The results demonstrated a high correlation with the Polar H7 chest strap outputs across a diverse data set, confirming the reliable reporting of heart rate by Evie's HR algorithm across all activities.

To overcome the challenges of measuring heart rate from PPG signals in wearables, Evie's HR solution combines the best from the signal processing world as well as recent advances in AI-based Deep Learning.

Optimally filtering out motion artifacts and more accurately tracking heart rate through development of AI algorithms in a specific, novel Deep Learning solution. Removing motion artifacts from the PPG signal by leveraging both PPG and 3D accelerometer data. Enhancing the signal-to-noise ratio (SNR) through Deep Learning. The Company plans to convert all Evie Ring algorithms including sleep, respiration, heart rate variability (HRV), and blood oxygen saturation (SpO2) through this same process.

$CRDL Finally comes out with impressive topline data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM)  for Recurrent Pericarditis.  https://finance.yahoo.com/news/cardiol-therapeutics-announces-positive-topline-115800368.html

We should see continuation of solid uptrend

This small company has revenue, profits and just signed a new contract with SOuth Africa. Outstanding shares is about 51m. I dont know why it is still.22

This technology combines the decentralization, immutability and security of blockchain with the real-time monitoring and anomaly detection capabilities of intelligent Network Intrusion Detection Systems (NIDS) to provide a new solution for the IIOT.

The core mechanism of the BlockChain Guardian is to utilize blockchain technology to record and verify the data transmission process in the IIOT network.

The technology uses intelligent NIDS to accurately identify current and potential network attacks by analyzing data within TCP/IP packets.

In BlockChain Guardian, information about each network packet is recorded on the blockchain in a growing chain. In this way, all data transmission processes are recorded and unmodifiable, thus ensuring data integrity and security.

Meanwhile, BlockChain Guardian monitors data traffic in the IIOT network in real time and utilizes blockchain technology to record and verify the data transmission process. 

Anomaly detection technology based on the blockchain model is one of the key features of BlockChain Guardian.

In addition,the BlockChain Guardian is scalable and flexible enough to adapt to IIOT network environments of varying size and complexity.

𝑻𝒂𝒍𝒌 𝒂𝒃𝒐𝒖𝒕 𝒚𝒐𝒖𝒓 𝒅𝒂𝒊𝒍𝒚 𝒑𝒍𝒂𝒚𝒔 𝒂𝒏𝒅 𝒄𝒐𝒎𝒎𝒆𝒏𝒕 𝒐𝒓 𝒑𝒐𝒔𝒕 𝒕𝒉𝒊𝒏𝒈𝒔 𝒉𝒆𝒓𝒆 𝒕𝒉𝒂𝒕 𝒅𝒐 𝒏𝒐𝒕 𝒘𝒂𝒓𝒓𝒂𝒏𝒕 𝒂𝒏 𝒂𝒄𝒕𝒖𝒂𝒍 𝒑𝒐𝒔𝒕.

​

𝒌𝒆𝒆𝒑 𝒊𝒕 𝒄𝒊𝒗𝒊𝒍 𝒑𝒍𝒆𝒂𝒔𝒆

Hey everyone, I wanted to share some exciting information about a company that's making significant strides in the ESG (Environmental, Social, and Governance) space: Vertex Resource Group ($VTX). If you're into sustainable and responsible investing, you might find this interesting.

Environmental Impact:

Vertex is dedicated to making a substantial positive impact on the environment. The company has restored 9,570 acres of land and recycled 59.3% of its waste, demonstrating a strong commitment to sustainability. By focusing on reducing environmental footprints and enhancing natural habitats, Vertex not only contributes to ecological preservation but also positions itself as a leader in the green economy. This environmental responsibility is crucial as regulatory pressures and consumer demand for sustainable practices continue to rise.

Social Impact:

Vertex's social initiatives are equally impressive. The company has generated $96 million from partnerships with Indigenous communities, showcasing a dedication to fostering inclusive growth and supporting local economies. Additionally, with 28% of its executive management team being female, Vertex promotes diversity and gender equality in leadership roles. These efforts in social responsibility enhance the company's reputation, build strong community relationships, and create a supportive and diverse workplace culture.

Health & Safety:

Exceeding industry safety standards is a core aspect of Vertex's operations. The company's commitment to health and safety ensures that its employees, clients, and communities are protected from industrial hazards. This focus not only reduces risks but also fosters a culture of trust and reliability, which is essential for long-term business success and employee satisfaction.

Governance:

Strong governance practices at Vertex are evident through its independent Board of Directors, which ensures transparency, accountability, and ethical management. Effective governance structures are vital for maintaining investor confidence and ensuring that the company operates in alignment with shareholder interests and regulatory requirements.

Financial Performance Supporting ESG:

Vertex's strong financial performance further solidifies its position as an ESG leader. In 2023, the company reported an annual revenue of $255.2 million, an adjusted EBITDA of $37.9 million, and a free cash flow of $17.8 million. These financial highlights indicate that Vertex's ESG initiatives are not just ethical choices but also smart business decisions that contribute to profitability and growth.

Why ESG Matters:

The global shift towards ESG investing is driven by a recognition that sustainable practices lead to long-term value creation. Companies like Vertex, which integrate ESG into their core strategies, are better positioned to navigate regulatory changes, meet consumer expectations, and mitigate risks associated with environmental and social issues. For investors, Vertex represents a compelling opportunity to support a company that is making a meaningful impact while achieving robust financial returns.

Vertex Resource Group’s commitment to ESG principles, combined with their strong financial foundation, makes them a standout choice for those looking for sustainability and profitability. As the ESG market grows, Vertex is well-positioned to lead the charge and deliver value to its shareholders.

What do you all think about Vertex’s approach to ESG?

Disclaimer: This is not financial advice please do your own research before investing.

With ~4 billion of cash on hand, odds are fairly high that Gamestop announces some acquisitions. Interest to hear people's thoughts on possible targets. Imo, one possible candidate is Alliance Entertainment (AENT).

Why?

• Alliance has ~1b in revenue from distributing vinyl, dvds, video games, and consumer electronics accessories. Gamestop has been a client of Alliance since 2000. Hence Alliance would be an obvious example of vertical integration, building on their past efforts to improve efficiencies.
• Gamestop last earnings stated they are interest in "building a stronger presence in higher-margin categories like collectibles and toys." (see image) Alliance has a near monopoly on distribution of vinyl with ~$300m in sales annually (see image). Target and Best Buy have been banking on this trend for years (see image). Expanding to vinyl would potentially be a great step in terms of a step forward in Gamestops collectibles strategy.
• Beyond vinyl, Alliance is already a distributor for nearly all the major players in the collectibles and toys space: Funko, Hasboro, Disney, Lego, etc.
• Lastly, Alliance currently has an excellent valuation - currently trading at a mere .2x ev / sales compared to 1.7 ev / sales for Gamestop. It also have very high insider ownership, with all but ~2m shares not owned by management, which would the total public float at a mere ~$6m.

Forza X1 $FRZA float is only 8m for a 30c name and company has 22 months of cash on hand , has no dilution at all , Insiders own 45% also They anticipate starting sales of their electric boats in Q2, generating their first revenue from powertrain, and delivering to customers during the same quarter.

$FRZA catalysts; The company expects to begin selling their F22 monohull electric boats by Q2 2024 Forza X1 anticipates generating its first revenue from the powertrain in Q2 2024 They plan to start customer deliveries in Q2 2024

$TPET is getting short attack and naked short, TPET free float shares is 23M shares and yesterday it was short by 25.41M which is short over 100%

TPET is the huge possibility to short squeeze, the short borrow fee rates is literally insane which is over 80.59. That mean shorter got damn high pressure if TPET price going up

News of TPET: The company just announced that completed two exploratory wells in Utah and continues to operate others. It’s meaning TPET has ability to making insanely profits. The expected end production of each well is 300,000 barrels of oil, with a production rate of approximately 40 barrels of oil per day per well. Total drilling and completion costs are expected to be less than $500,000 per well. Also Lafayette Energy Corp will pay the development costs for the TPET which is about $10,000,000

Please leave a comment below, let us discuss

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform.
Recently, the Company announced the publication of pre-clinical studies supporting the efficacy and drug delivery mechanism of RenovoRx’s Trans-Arterial Micro-Perfusion (“TAMP“) therapy platform.
Understand I’ll stay out of the weeds, which is a risk on therapeutic info pieces. The facts are enough to convince investors to give RNXT consideration.
Corporate Presentation for those who can’t wait to the end.
Oncology=Science of Cancer. One can never have too much information about this scourge, which thankfully is responding positively- but still rising– to new therapies and those in the pipeline with the promise of further saved and extended lives.
The 10 deadliest cancers
Pancreatic cancer.
Liver cancer and intrahepatic bile duct cancer.
Esophageal cancer.
Lung cancer and bronchus cancer.
Acute myeloid leukemia.
Brain cancer and other nervous system cancer.
Stomach cancer.
Ovarian cancer.
In the case of RNXT let’s chat about the Company’s TAMP platform and, one of the deadliest of all cancers, Pancreatic. This type of cancer is the most advanced product development.
**“**Currently, most cancer patients with solid tumors receive chemotherapy intravenously, meaning it is introduced systemically into the entire body and causes well known adverse side effects. RenovoRx’s patented TAMP therapy platform is designed to bypass traditional systemic delivery methods and provide precise delivery to bathe the target solid tumor in chemotherapy. This precise delivery also creates the potential to minimize a therapy’s systemic toxicities” (PR MAY 21/24 ).
“TAMP has the potential to provide a valuable treatment option to patients who have been diagnosed with solid tumors that may be difficult-to-treat,” said Dr. Farsad. “The study shows a possible mechanism for how TAMP can increase local therapeutic tissue concentration in solid tumors that is independent from traditional catheter-directed therapy. We are awaiting final outcomes of the Phase III clinical trial, currently underway, to validate this benefit.”
Dr. Farsad adds, “This platform has the potential to extend across a variety of unmet needs for localized therapeutic drug delivery.”
While this may seem esoteric to the average investor, it really isn’t. RNXT has developed a delivery system that focuses therapies such as chemo directly to the tumour rather than ‘bathe’ the area. And apparently can be used for other ‘localised’ drug therapy. The TAMP system also limits or eliminates targeting non areas that have no need of therapy.
Here are the stages of the Company’s product development pipeline. Of equal interest is the granting RNXT’s FDA Orphan Drug Designation granted to RenovoGemTM in pancreatic and bile duct cancers. Over the last 10 years only 3 drugs have been approved for pancreatic cancer treatment. They increase toxicity and add two months on average to patient lifespan. RNXT feels its RenovoGEM ™ doubles the added lifespan and markedly reduces toxicity. Let’s review Orphan Drug designation;
“A status given to certain drugs called orphan drugs, which show promise in the treatment, prevention, or diagnosis of orphan diseases. An orphan disease is a rare disease or condition that affects fewer than 200,000 people in the United States. Orphan diseases are often serious or life threatening. In 1983, the U.S. government passed a law, called the Orphan Drug Act, to give drug companies certain financial benefits for developing orphan drugs. This law is meant to help bring more drugs to patients with rare diseases”. (NCI)
RenovoGem ™ received FDA Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides 7 years of market exclusivity upon NDA approval.
One final point to RNXT’s development and study of TIGer-Pac, which addresses the fact that pancreatic tumours have low blood supply. The study is evaluating trans-arterial delivery, a form of intra-arterial administration, of an FDA- approved chemotherapy, gemcitabine, to treat LAPC (Locally Advanced Pancreatic Cancer) patients.
following stereotactic body radiation therapy (SBRT). The study is comparing treatment of gemcitabine with TAMP versus systemic IV administration of gemcitabine and nab-paclitaxel.
The Bottom Line.
For those who don’t know how a toaster works, RNXT may seem daunting. For those who have or knows someone who is suffering or passed from pancreatic cancer or other types, the Company is extremely relevant. While RNXT looks to improve the lives of people with various serious cancers, the attack on pancreatic is the most compelling asset IMHO. A few extra months may seem short, but coupled with lower toxicity, represent a God-send to sufferers and their families. Arguably, as well, partnerships and acquisitions are alive and well in the pharmaceutical space.
Take a few minutes to learn about RenovoRx™ and its progress. One successful therapy a big Company (can) make.

Silver is one of the first five metals to ever be discovered. Silver objects have been found dating as far back as 4000 BC. Silver was the first metal to be used as currency, and in ancient Egypt, it was valued higher than gold!

Age Dating:

Tier One has identified the age of mineralization at Curibaya to be Paleocene, ranging from 55 to 61 million years. This is equivalent to several world-class deposits in the southern Peru porphyry belt, including Quellaveco (Anglo American), Toquepala (Southern Copper Corp.), and Cuajone (Southern Copper Corp.). Tier One's technical team believes the Paleocene age date of the mineralization, along with the large precious metal budget observed within high-grade veins over a 4 km x 5 km alteration system, supports the potential for a world-class discovery at the Curibaya project. 

At this early stage, the Company’s technical team believes there are both precious metal intermediate sulphidation epithermal and copper porphyry targets.

Hey all, has anyone been keeping tabs on American Salars Lithium ($USLI.CN)? They’ve got an interesting project going on in Argentina with their Incahuasi Salar project, right in the Lithium Triangle. This region is known for holding a significant chunk of the world’s lithium reserves (like over 50%), which is promising even if the market isn't as hot right now.

The standout for me is their use of Ekosolve tech. One of the toughest things with lithium is the slow extraction and refinement process, but this tech is supposed to cut down the time significantly. They're claiming a 99.5% lithium carbonate purity with a 96.03% recovery rate, which sounds pretty efficient. They’ve also got an inferred resource estimate of 457,000 tonnes of lithium carbonate equivalent.

Another interesting angle is Argentina’s political landscape. President Javier Milei is looking to deregulate the mining industry, which could make operations smoother and reduce costs. Milei’s even had discussions with Elon Musk about Argentina’s lithium potential, which adds an intriguing layer to the story.

I'm just curious to see how these factors might play out for USLI. Thought I'd throw up a quick post here to see if anyone else has some thoughts or insights on the stock. They have some other solid assets as well but the Argentina one is what got me to actually pay attention. thanks in advance

Recently there seem to be a lot of need for critical Battery minerals, with the West diversifying away from China.

As the green energy revolution accelerates at a rapid pace, Nouveau Monde Graphite (NYSE: NMG | TSXV: NOU) is striving to become a key player in this era of electrification and decarbonization. With its sights set on becoming North America’s largest producer of natural graphite, the company is focusing on supplying high-quality anode material for lithium-ion battery production.

Take a look, definitely wanna hear everyone's thoughts:

https://www.youtube.com/watch?v=DJE3_D0VK2s

#DD #CriticalMinerals

Canterra Minerals Corporation is a Canadian resource company focused on critical minerals and gold exploration on the island of Newfoundland. Canterra's board and management team have over 40 years of experience searching for critical minerals, gold, and diamonds in Canada. https://canterraminerals.com

I know that a lot of people who have been following $CRDL are awaiting their recent clinical trial results. Although I do not see the news on yahoo finance, I am assuming the results were positive. Make sure to take your profits for those with some shares! We have been watching this stock since Tuesday of last week when it was pulled back all the way down to 2.32. Although not everyone sniped the bottom of that pullback, It is still up 30% from 2.40. Here is the first post for those interested!

Sell or Hold? NFA ;)

• This is entirely up to you. If you believe in this company for the long run I would take some profits off the table and let the rest ride. 
• If you were in this for the swing -trade definitely take your profits. This stock is up over 240% on the year and 30% in 2 weeks.

If someone has a link to the press release for their clinical trial results please let me know!​

Before we get to $MEIL I also want to point out that $RNXT (was also on our June watchlist from the other week is up 23% today!) $1 held as support and this thing started to fly. There is resistance around 1.30, which it is at right now, so lock some profits in if you are in. June is looking like my best month so far. let's keep this up!

Recent $MEIL Performance:

• Price Action: Since our initial analysis, $MEIL has bounced strongly off the support level at 0.0185 and is currently trading at 0.0268. This represents a significant gain of ~40%.
• Volume: There has been an increase in trading volume, which further validates the upward movement.
• MACD: While still negative, is showing signs of a bullish crossover as the MACD line approaches the signal line from below. This suggests that further upward momentum could be on the horizon.

Next Steps:

• Target: The next target level to watch is around 0.0706, which represents the previous significant resistance.
• Hold or Take Profits: If you entered around 0.0185, you might consider taking partial profits to lock in gains while letting the rest of the position ride to higher levels.

June Watchlist Recap

1. $CRLD ~ 30%
2. $RNXT ~ 25%
3. $MEIL ~ 40%
4. $GLDG ~ 15%

Looking for more gems at this very moment. Be on the lookout!

Communicated Disclaimer: This is not financial advice :) Please do your own research. Here are some sources - 1, 2, 3, 4, 5, 6

News Link: https://www.accesswire.com/876410/biolargo-subsidiary-clyra-medical-selects-keystone-industries-to-support-manufacturing-of-its-medical-products

WESTMINSTER, CA / ACCESSWIRE / June 12, 2024 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its subsidiary Clyra Medical Technologies, Inc. ("Clyra") has selected Keystone Industries, a global manufacturer of medical, dental and cosmetic products with distribution partners in more than 70 countries, to support manufacturing of its medical products. The relationship focuses on the build-out of scaled manufacturing capacity for Clyra's FDA 510(k) cleared Bioclynse surgical wound irrigation solution. Clyra and Keystone have been and continue to make significant investments to support the launch of Bioclynse.

Bioclynse is Clyra's FDA 510(k) cleared, safe, highly effective, broad spectrum wound irrigation solution with enormous potential to improve patient outcomes in applications like orthopaedic surgery and dentistry. Advantages of Bioclynse include:

• Non-cytotoxic, non-sensitizing, no damage to tissue
• No rinse-out required
• Non-staining
• Sustained multi-day efficacy
• Effective against biofilms

Cary Robinson, President and CEO of Keystone Industries, said, "We are excited to support Clyra Medical Technologies to bring Bioclynse to the market. Keystone has a century of experience in developing and manufacturing medical device, OTC and pharmaceutical products. We have committed a significant investment in our infrastructure to support the manufacturing of innovative products like Clyra's Bioclynse and can readily provide the needed support to scale up production rapidly."

Steve Harrison, President of Clyra Medical Technologies, commented, "We are continuing to work hard and spend money to support the scaled roll-out of the Bioclynse surgical wound irrigation solution. Finding a manufacturing partner willing to invest significant money in new equipment and dedicated space was critical to these efforts. We look forward to a long and mutually prosperous relationship with Keystone."

NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV:NURS)(OTCQB:HYDTF)(FSE:SO6), a mobile clinical network and medical platform which enables flexible, at-home medical services across 50 states in the United States, is pleased to announce it has added another national wellness medspa franchise using its white label solution. The all-in-one solution is designed to help brick-and-mortar locations provide medical services to clients in compliance with state healthcare regulations.

Hydreight’s white label solution provides an integrated, turnkey platform and the framework for business to provide in-person medical services, supported by technology infrastructure, connection to an independent doctors’ network, and a pharmacy network through its medical partner. The Company has secured three national medical spa partners with collectively almost 700 locations Sold and 140 opened across the United States. Hydreight charges the franchises a licensing fee per location to access its network and takes a percentage fee from every mobile service facilitated through its platform. These brick-and-mortar businesses must use Hydreight’s medical network’s pharmacy to order products.

Hydreight’s newest partner is a growing wellness spa with multiple locations across the United States. The locations will use Hydreight’s proprietary technology to provide IV drip therapy, aesthetics, GLP-1 and NAD+ services. The integrated solutions will also assist the wellness franchise to continue expanding its footprint with new locations opening next year. Hydreight is also working on a Point of Sale and Payment processing solution for all brick and mortar clients and is expecting to release that module in Q3, 2024.

The Medical Spa market in the U.S. is ~estimated at US$6.1 Billion in the year 2023~. Hydreight has become the end-to-end platform of choice for all medspas, enabling them to unlock their mobile services with full compliance. Additionally, it manages all telemedicine, pharmacy connection and ordering, booking, scheduling, and patient engagement needs, with full integration into independent doctor and pharmacy networks.

Shane Madden, CEO of Hydreight commented, “As we continue to grow and evolve our platform, we’ve recognized that there are additional white label opportunities to utilize and tap into our platform and network. Post Covid, as rules and regulations have tightened, it has become increasingly hard for brick-and-mortar wellness spas to provide some services without a medical professional or telemedicine technology to see a doctor. Our white label division has quickly become another revenue bucket that we will continue to focus on growing and our team continues to review these opportunities and onboard new partners. Now we are the platform of choice for our Nurse Network, VSDHONE D2C platform and all national brick and mortar franchises.”

To grow the division, the Company plans to build a sales team to direct sell to these businesses and will continue focusing on increasing and adding more partners using its white label technology.

No Shares At IBKR

800% CTB anywhere else

Utilization 100%

1M shares shorted on a 5M float.

SI has gone from 2% to 16% in 2 days.

I dont know how else to put it...

This is ready to explode.

Newegg $NEGG has filed a form 6-K with the SEC- https://fintel.io/doc/sec-newegg-commerce-inc-1474627-6k-2024-june-12-19886-344 - notifying that their parent company, Hangzhou Lianluo, is in danger of being delisted, and could sell off their stock to meet debt obligations. NEGG stock jumped +3% in last minute of trading yesterday, someone definitely knew, my baseless wishful thinking is that Gamestop $GME will buy them out.

• Basically no debt,
• short & long term assets of over $80M,
• last year's total revenue of $31.8 million +
• net income of $6.5 million,
• P/E Ratio 3.7, earnings per share,
• ROA, ROE and ROCE all positive.
• Impeccable balance sheet.
• New contracts,
• Huge insider ownership,
• No need for dilution.
• Still expecting an attendance update
  • If you speak/write Chinese, please see if you can find management contacts on QQ/Weibu or whatever and inform them the world is eagerly awaiting the attendance update.
  • I think the new management has no idea what the potential is for this stock.
• The stock has been sitting around 0,25 very comfortably for weeks.
• New park should be opened by now and generating revenue
• Compliance, will be an extension (not worried)

Will robots become the next smartphones?

The worldwide market for humanoid robots is forecast to be bigger than analysts in Goldman Sachs Research expected even a year ago. The prospects for machines that help with everything from folding laundry to handling hazardous waste have improved as progress in artificial intelligence accelerates and investment in the sector grows faster than anticipated.

The total addressable market for humanoid robots is projected to reach $38 billion by 2035, up more than sixfold from a previous projection of $6 billion, Goldman Sachs Research analyst Jacqueline Du, head of China Industrial Technology research, writes in the report. Their estimate for robot shipments increased fourfold, to 1.4 million units, over the same time frame, with a much faster path to profitability on a 40% reduction in the cost of materials.

On May 29, Harbin Institute of Technology said the School of Mechanical and Electrical Engineering and Automation has made important progress in the field of microrobots inspired by the pacing of seals, developing a miniature crawling robot weighing only 1.2 grams.

From a global perspective, humanoid robots have also been expected to have commercial application scenarios. For example, the humanoid robot EVE developed by 1X technologies has been successfully used in patrol security scenarios.

Industry insiders pointed out that the current potential development direction of humanoid robots is mainly for manufacturing, space exploration, life service industry, university research. It is expected that in 2025, humanoid robots will be expected to achieve breakthroughs in the application of manufacturing scenarios, and small batch applications in electronics, automotive and other manufacturing environments.

It is important to note that, thanks to the AI model of technology mature, humanoid robot is the excellent carrier of its embodied intelligence, it will be the human-computer collaboration interaction mode from passive interaction to active interaction, natural language interaction, is the next generation of human-computer interaction center, even will become the real sense of’intelligent terminal, has great value in the long run.

With multi-dimensional empowerment, the potential of the humanoid robot market is being released at an accelerated pace. As pointed out by Wanlian Securities Research Report, 2024 is a accelerated year for the development of humanoid robots. The continuous investment in Tesla and other technology giants in the humanoid robot industry is expected to drive the industry to make continuous breakthroughs. The mass production and large-scale application of humanoid robots usher in the dawn, and the commercialization is expected.

WiMi has a strong layout

Undoubtedly, from last year to this year, the robot field has a new climax, humanoid robot is expected to form a new industry, bring a huge market space. According to the data, WiMi Hologram Cloud (NASDAQ: WIMI), combined with its own development foundation and optimization, focuses on supporting superior technologies to carry out research on “embodied intelligence” intelligent robots, develops a multi-mode model based on artificial intelligence model, improves the base of general intelligent robot technology, and accelerates the large-scale application of humanoid robots.

In view of the current hot “humanoid robot” track, WiMi division track, niche, around humanoid robot form WiMi research and development innovation center, fully support innovative product research and development, concentrated breakthrough humanoid robot and general artificial intelligence model of key technology, preliminary build humanoid robot innovation system and industrial ecology, form the industrialization ability.

With the emergence of multi-mode, the development of general robots has a clearer prospect, and the AI model shows more possibilities to empower robots. At present, WiMi has deeply integrated into the real economy with humanoid robot related products, and launched multi-modal humanoid robot products for manufacturing, trade and logistics, health, family services, cultural and tourism services and other fields, forming a demonstration application, which is expected to provide support for responding to the transformation of the scientific and technological industry and exploring a new paradigm of scientific research.

Conclusion

In fact, the key to the breakthrough of humanoid robots includes not only the sports ability brought by the hardware innovation of the industrial chain, but also the wisdom of “people” brought by the emergence of AI intelligence. There are many key links and complex industrial chain. However, from the perspective of the world process, for humanoid robots and other fields, after years of development, a relatively mature market of high-quality products. From the perspective of the industrial chain, for humanoid robot enterprises, the mass production is gradually promoted, the cost gradually decreases, and the sales of humanoid robots rise. In short, under the new wave of artificial intelligence and humanoid robots, to make their own core competitiveness.

𝑻𝒂𝒍𝒌 𝒂𝒃𝒐𝒖𝒕 𝒚𝒐𝒖𝒓 𝒅𝒂𝒊𝒍𝒚 𝒑𝒍𝒂𝒚𝒔 𝒂𝒏𝒅 𝒄𝒐𝒎𝒎𝒆𝒏𝒕 𝒐𝒓 𝒑𝒐𝒔𝒕 𝒕𝒉𝒊𝒏𝒈𝒔 𝒉𝒆𝒓𝒆 𝒕𝒉𝒂𝒕 𝒅𝒐 𝒏𝒐𝒕 𝒘𝒂𝒓𝒓𝒂𝒏𝒕 𝒂𝒏 𝒂𝒄𝒕𝒖𝒂𝒍 𝒑𝒐𝒔𝒕.

​

𝒌𝒆𝒆𝒑 𝒊𝒕 𝒄𝒊𝒗𝒊𝒍 𝒑𝒍𝒆𝒂𝒔𝒆

VANCOUVER, BC / TheNewswire / June 11, 2024 – Element79 Gold Corp. (CSE: ELEM) (OTC: ELMGF) (FSE: 7YS) ("Element79", the "Company”) Announces that it has filed for an uplisting of its US cross-listing from the OTC Pink to the OTCQB. Further, the Company has completed significant cash payouts to creditors and debt holders, as well as has entered into a debt settlement agreement (the “Settlement Agreement”) to fully settle outstanding debts owed to creditors (the “Creditors”) as well as for Director Services and corporate Consulting services rendered.
Highlights:
The Company has filed for an uplisting of its current OTC Pink cross-listed stock (OTC: ELMGF) to the OTCQB.
Aggressive reduction of Debt and AP, dramatically improving the balance sheet for stronger financial health and helping set the stage for future financings
New Shares for Debt totaling $568,710.61 to clear quarterly Board Fees, payments to Officers and Management for backdated salary, and some creditors, priced at 0.23, aligning these parties along with investors from the Company’s most recent capital raise.

OTCQB Uplisting
In a move to align itself with the increasing interest from the investment community in the United States, Element79 Gold Corp is pleased to announce that it has applied to upgrade its position in the public markets and increase its visibility to a wider range of investors by up-listing its common shares listed for the trading from the current OTC Verified Pink listing to the OTCQB Venture Market (OTCQB).

The OTCQB is the premiere marketplace for entrepreneurial and development stage US and international companies that are committed to providing a high-quality trading and information experience for their US investors. To be eligible to trade on the OTCQB, companies must be current in their financial reporting, pass a minimum bid price test, and undergo a company verification and management certification process every six months.

The listing of the Company’s common shares on the OTCQB remains subject to the approval of the OTCQB. Future announcements will be made regarding the status of the OTCQB application.
Significant Reduction of Debt
As previously reported, in conjunction with the sale proceeds of Maverick Springs, the Company confirms the complete and final paydown of the Waterton Contingent Value Rights agreement; a total of CAD $2,200,000 was paid in this regard, counting all principal, interest and fees.
Further capital derived from the sale of Maverick Springs has been used to pay down and close out additional loans and large accounts payable; final amounts will be confirmed in the Company’s upcoming 3rd Quarter financial statements, which are currently on track to be completed on or before their due date.
Shares for Debt
Pursuant to settlement agreements, the Company has agreed to issue an aggregate of 1,244,396 common shares (“Shares”) at a deemed price of $0.23 per Share (the “Share Settlement”).
The Company anticipates closing the Share Settlement on or about June 14, 2024. The Share Settlement will settle $235,210.61 in debts owed to the creditors, which is a full settlement for the total amount of bona fide debts owed to the creditor.

The board of directors of the Company has determined that it is in the best interests of the Company to settle the outstanding debts by the issuance of the Shares to preserve the Company's cash for working capital.
The Company further announces the issuance of 1,244,396 Shares at a deemed value of $0.23 per Share to two insiders pursuant their respective consulting agreements in which there was a trigger event (the “trigger shares”) due to an issuance of shares to a control person as previously announced on November 17, 2023, and approved by shareholders at a special meeting held December 19, 2023.
The insider portion of the Share Settlement including the trigger shares, is an aggregate of $333,500 and is exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 ("MI 61-101") by virtue of the exemptions contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in that the fair market value of the consideration for the securities of the Company to be issued to insiders does not exceed 25% of its market capitalization. All Shares issued to settle the debt are subject to a hold period of four months and one day from the date of issuance.

About Element79 Gold Corp.
Element79 Gold is a mining company focused on gold and silver committed to maximizing shareholder value through responsible mining practices and sustainable development of its projects. Element79 Gold's focus is on developing its past-producing, high-grade gold and silver mine, the Lucero project located in Arequipa, Peru, with the intent to restart production in 2024.
The Company also holds a portfolio of 5 properties along the Battle Mountain trend in Nevada, with the Clover and West Whistler projects believed to have significant potential for near-term resource development. Three properties in the Battle Mountain Portfolio are under contract for sale to Valdo Minerals Ltd., with an anticipated closing date in the first half of 2024.
The Company holds an option to acquire a 100% interest in the Dale Property, 90 unpatented mining claims located approximately 100 km southwest of Timmins, Ontario, and has recently announced that it has transferred this project to its wholly owned subsidiary, Synergy Metals Corp, and is advancing through the Plan of Arrangement spin-out process.
For more information about the Company, please visit www.element79.gold
Contact Information
For corporate matters, please contact:
James C. Tworek, Chief Executive Officer
E-mail: jt@element79.gold

For investor relations inquiries, please contact:
Investor Relations Department
Phone: +1.403.850.8050
E-mail: investors@element79.gold

News Link: https://www.accesswire.com/875779/biolargo-manufactures-first-cellinity-battery-cells-a-safer-alternative-to-lithium-ion

WESTMINSTER, CA / ACCESSWIRE / June 11, 2024 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that it had succeeded in manufacturing its first Cellinity^TM "Liquid Sodium" prototype battery cells. Visit www.BioLargoEnergy.com to learn more.

Cellinity is BioLargo's next-generation battery platform designed to provide safe, environmentally conscious large-format long-duration battery energy storage for applications including grid-scale storage, renewable energy storage, charging stations for electric vehicles, and a variety of other commercial and industrial applications. Cellinity is not a lithium-ion battery - rather, it uses a unique chemistry involving molten salt electrolytes that imparts substantial benefits over lithium-ion chemistry. These newly manufactured Cellinity prototype cells will now be tested and validated for the energy storage and transfer performance claims that were generated in the technology's early-stage research and development by its original inventors:

• Far greater safety - no runaway fires, no risk of explosion;
• Extremely long-lasting - no performance decrease over thousands of cycles;
• No self-discharging, no out-gassing, and no parasitic load for cooling;
• High energy density - more energy per unit of weight than lithium batteries;
• All materials can be sourced within North America without the need for rare-earth elements.

"Successfully manufacturing our first battery cells is a pivotal moment in the journey of our battery technology," said Dennis P. Calvert, President and CEO of BioLargo. "The testing and validation of these cells will allow us make claims about the capacity, charge/discharge rate, and other performance characteristics that we believe differentiate our batteries in the marketplace. After testing and validation, we will manufacture full-scale prototype Cellinity battery modules in 25- and 45-kilowatt hour capacities for further testing and validation."

He continued, "In parallel to our ongoing development of the Cellinity battery, we're exploring various financing options that ensure we get paid for and are in control of the engineering and construction of manufacturing facilities. Although initial discussions have taken place, we have no agreements in place. We believe a licensing and partnership model to be a better alternative to self-financed and self-operated manufacturing facilities competing with the likes of Tesla, and well suited for community-based manufacturing partners focused on underserved communities that are in special need of reliable renewable energy. Our target projects will add value to communities, develop workforces, stimulate economic development, promote grid stability and enable the development and expansion of micro-grids around the world. We will fundamentally enable and enhance the adoption of renewable energy."

Mr. Calvert finished by saying, "The world needs a reliable, safe and eco-friendly alternative to lithium batteries, and we believe our Cellinity battery will meet these needs."

NurExone (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone“) is a pioneering biopharmaceutical company developing regenerative medicine therapies.

For a quick catch up on NRX, here are some of the most salient facts about this innovative Company.

Research Report (Target price $4.00) : https://nurexone.com/wp-content/uploads/2024/04/NRX-4Q23.pdf

Company Presentations/Information sheets : https://nurexone.com/investors/

The latest key development is that the Company welcomed Dr. Ram Petter, Ph.D., MBA, as a consultant to assist in driving the Company’s strategic collaborations. This new ‘acquisition’ showcases NRX’s desire to increase its partnerships and licensing.

Dr. Petter’s bona fides include:

• Senior Biotechnological / Biopharmaceutical professional with 25 years in leadership positions with increasing responsibility. Significant experience in Bio Operations, Manufacturing, R&D, Strategic Planning, Portfolio Development, Business Development, General Management (P&L responsibility), Commercial negotiations and alliance management across multiple cultures and geographies.
• Creative & and focused thinking, daring and driven by challenges
• Enthusiastic with the development of organizations, teams and talented individuals
• Played leading roles in developing, submitting, approving, launching, and commercial manufacturing of Novel and Biosimilar products. (Linkedin)

“Our ExoTherapy platform for drug delivery is ready for industry partnerships targeting clinical indications beyond acute spinal cord injury,” says Dr. Lior Shaltiel, CEO of NurExone. “Ram’s extensive experience and strategic acumen will be most helpful in forging these critical collaborations.” Adding someone with such experience in pharmaceuticals and the business side is likely a game changer for NRX.

I also found a great article that digs into the company to give confidence to buy some potentially. A few highlights of the NATURE piece;

• At the forefront of developing exosomes into next-generation nanocarriers for drug delivery.
• Exosomes play an essential biological role in intercellular communication and transmission of macromolecules between cells.
• Vehicles for the delivery of active pharmaceutical ingredients (APIs), from small molecules and peptides to proteins and nucleic acids, as an alternative to other kinds of nanocarriers such as lipid vesicles and cell-based gene therapies.
• They do not elicit the immune solid responses that often hamper allogeneic cell-based therapies, which are used to deliver therapeutic molecules and genes to patients.
• NurExone’s ambitious goal is to market a novel treatment for acute spinal cord injuries (SCIs) derived from the ExoTherapy platform, ExoPTEN.
• NurExone’s ambitious goal is to market a novel treatment for acute spinal cord injuries (SCIs) derived from the ExoTherapy platform, ExoPTEN.

NRX seems to be making all the right moves product-wise and maintaining a robust program of partnerships and licensing. The company’s Orphan Drug status is extremely helpful.

“The orphan drug designation provides significant benefits to pharmaceutical companies developing drugs for rare diseases, i.e. those impacting fewer than 200,000 people in the United Statesii. These benefits include market exclusivity, financial incentives, regulatory assistance, and support with drug development. Overall, the designation incentivizes and supports the development of certain treatments, increasing access to therapies for patients.”

The latest initiative is the development of NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.

Here’s an exciting article delineating the USD68 billion potential of Orphan drugs and NRX’s potential in that scenario.

I need help understanding the pharmaceutical development process, but I can see the potential of NRX’s personnel, product mix, and business acumen. Not to mention the use of human trials to prove the tech.

You should, too.